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 Deoxyribonucleic acid obtained from
2 large DCM families was studied using
whole-exome sequencing and cose-
gregation analysis resulting in the iden-
tiﬁcation of a novel disease gene, FLNC.
The 2 families, from the same Italian
region, harbored the same FLNC splice-
site mutation (FLNC c.7251D1G>A).
 A third U.S. family was then identiﬁed
with a novel FLNC splice-site mutation
(FLNC c.5669-1delG) that leads to
haploinsufﬁciency as shown by the FLNC
Western blot analysis of the heart muscle.
 The FLNC ortholog ﬂncb morpholino was
injected into zebraﬁsh embryos, and when
ﬂncb was knocked down caused a cardiac
dysfunction phenotype.
 On electron microscopy, the ﬂncb
morpholino knockdown zebraﬁsh heart
showed defects within the Z-discs and
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AB BAND ACRONYM S
DCM = dilated cardiomyopathy
DNA = deoxyribonucleic acid
dpf = days post-fertilization
FLNC = ﬁlamin C
flnca = ﬁlamin Ca
flncb = ﬁlamin Cb
GFP = green ﬂuorescent
protein
= hypertrophic
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MaA genetic etiology has been identiﬁed in 30% to 40%of dilated cardiomyopathy (DCM) patients, yet only 50%of
these cases are associatedwith a known causative gene variant. Thus, in order to understand the pathophysiology
of DCM, it is necessary to identify and characterize additional genes. In this study, whole exome sequencing in
combinationwith segregation analysiswas used to identifymutations in anovel gene,ﬁlaminC (FLNC), resulting in
a cardiac-restricted DCM pathology. Here we provide functional data via zebraﬁsh studies and protein analysis to
support a model implicating FLNC haploinsufﬁciency as a mechanism of DCM. (J Am Coll Cardiol Basic Trans
Science2016;1:344–59)©2016TheAuthors. PublishedbyElsevier onbehalfof theAmericanCollegeofCardiology
Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).omyopathyHCM
cardihpf = hours post-fertilization
LoF = loss-of-function
MFM = myoﬁbrillar myopathy
MO = morpholino
RF = retrograde fraction
RNA = ribonucleic acid
RT-PCR = real-time
polymerase chain reaction
SV = stroke volume
TEM = transmission electron
microscopy
WES = whole exome
sequencingD ilated cardiomyopathy (DCM) is a severedisease of the heart muscle characterizedby ventricular enlargement and systolic
dysfunction leading to progressive heart failure and
is among the most common causes of cardiovascular
mortality (1,2). Approximately 30% to 40% of cardio-
myopathy cases are familial and attributable to ge-
netic causes (3), and over 30 genes have been shown
to cause DCM. However, approximately 50% of DCM
cases have unknown causative mutations (4). This
apparent gap in our understanding of the disease
has prompted ongoing studies to identify additional
DCM candidate genes (5,6).
One such novel candidate gene is ﬁlamin C
(FLNC), which encodes the structural protein FLNC,
an actin-crosslinking protein within the sarcomere of
striated muscle. FLNC is located on the chromosome
region 7q32–q35 (7). Until recently, deletion/inser-
tion frameshift, point, and nonsense FLNC muta-
tions have only been reported in association with
isolated skeletal distal and myoﬁbrillar myopathy
diagnoses (8–12). However, in 2014, Brodehl et al.
(13), identiﬁed 2 missense variants (p.S1624L;
p.I2160F) in 2 families with restrictive cardiomyop-
athy in the absence of skeletal muscle defects and
Valdes-Mas et al. (14) identiﬁed several FLNC
missense variants (plus 1 stopgain) in several famil-
ial hypertrophic cardiomyopathy (HCM) cases. These
cardiac-speciﬁc studies support FLNC as a candidate
gene causing cardiomyopathies and provide evi-
dence that FLNC-related pathology may operate
through a variety of mechanisms. The present study1 RR025780, UL1 TR001082, R01 HL69071, R01 116906 to Dr. Mestroni
titute grants K23 JL067915 and R01HL109209 to Dr. Taylor. The human
tutes of Health/National Center for Advancing Translational Sciences Colo
1 TR001082. Funding was also received from CRTrieste Foundation and G
pported in part by a Trans-Atlantic Network of Excellence grant from the
orted that they have no relationships relevant to the contents of this pap
nuscript received December 26, 2015; revised manuscript received Aprilreports FLNC mutations in cardiac-restricted
DCM, thus adding to the growing evidence
supporting a role for the FLNC gene in
cardiomyopathy.
In this study, we report the identiﬁcation
of a FLNC splicing variant by whole exome
sequencing (WES) in 2 DCM families from the
same geographic region of Italy. A second
FLNC splicing variant was identiﬁed in a U.S.
DCM family. All affected family members
from each of the 3 families expressed a
cardiac-restricted DCM phenotype with no
evidence of skeletal muscle involvement.
The pathogenic mechanism of these FLNC splicing
variants is not deﬁnitively elucidated, but reduced
cardiac FLNC protein levels in 1 patient is suggestive
of a haploinsufﬁciency model. A haploinsufﬁciency
model is supported by the morpholino (MO) knock-
down of the zebraﬁsh FLNC ortholog (ﬂncb) leading
to a cardiac-disrupted phenotype.
METHODS
STUDY SUBJECTS. Six individuals from 2 Italian
families (Figures 1A and 1B) underwent WES. Two
more individuals from a U.S. family (Figure 1C)
underwent genetic analysis using Illumina TruSight
One Sequencing Panel (San Diego, California), which
queries 4,813 genes associated with clinical pheno-
types. Families were selected from the Familial
Cardiomyopathy Registry, a multicenter, 3-decade-
long ongoing project studying human hereditary, and Colorado Clinical and Translational Sciences
cardiac tissue bank was supported by National In-
rado Clinical and Translational Science Awards grant
ENERALI Foundation to Dr. Sinagra. This work was
Leducq Foundation (14-CVD 03). The authors have
er to disclose.
28, 2016, accepted May 2, 2016.
FIGURE 1 Family Pedigrees TSFDC029, TSFDC031, and DNFDC057
Squares and circles indicate male and female subjects, respectively, and shading indicates a dilated cardiomyopathy phenotype. The arrowheads indicate probands. Plus
and minus signs indicate carriers (þ) or noncarriers (–) of the ﬁlamin C (FLNC) variant, respectively. Individuals II:2, III:4, and IV:1 in family TSFDC029 (A); individuals II:2,
II:3, and III:1 in family TSFDC031 (B); and individuals II:1 and II:2 in family DNFDC057 (C) underwent whole exome sequencing, and are indicated by an *. Reported ages at
death are indicated. (D) Electrocardiogram of subject TSFDC031 III:1 showing atrial ﬁbrillation, which ﬁrst occurred at the age of 21 years, and (E) the 2-dimensional
echocardiogram images showing a mildly enlarged left ventricle with a left ventricular ejection fraction of 40% (age 36 years). LVEDD ¼ left ventricular end-diastolic
diameter; LVEDV ¼ left ventricular end-diastolic volume; NCD ¼ noncardiac death; SCD ¼ sudden cardiac death.
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346cardiomyopathies. The diagnosis of DCM was made
on the basis of the 1999 consensus criteria of the
Guidelines for Familial Dilated Cardiomyopathy and
evaluation of all available living subjects by in-
vestigators (15).
Clinical data collected included medical history,
family history, physical examination, and medical
data, including laboratory, electrocardiogram, and
echocardiogram diagnostics (15). Skeletal muscle
development was systematically evaluated by a
comprehensive physical examination and routine
serum creatine kinase testing. Medical records from
deceased and living subjects were reviewed when
available. Criteria for the diagnosis of DCM were
presence of left ventricular fractional shortening<25% and/or an ejection fraction <45%, and left
ventricular end-diastolic diameter >117% of the pre-
dicted value per the Henry formula (16). Exclusion
criteria included any of the following conditions:
blood pressure >160/110 mm Hg; obstruction >50%
of a major coronary artery branch; alcohol intake
>100 g/day; persistent high-rate supraventricular
arrhythmia; systemic diseases; pericardial diseases;
congenital heart diseases; cor pulmonale; and
myocarditis. Informed consent was obtained from all
living subjects and local institutional review boards
approved the protocol.
WHOLE EXOME SEQUENCING AND BIOINFORMATICS
ANALYSIS. Genomic deoxyribonucleic acid (DNA) was
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347extracted, and WES was performed and analyzed
using previous published methods (17). Paired-end
sequencing was targeted for a depth of about 100
reads (actual coverage 20 to 64). The referenced
human genome sequence was used in the Genomic
Short Read Nucleotide Alignment Program (GSNAP;
version 2012-07-20, Thomas Wu/Genentech Inc.,
South San Francisco, California) (18). Gene lists were
initially created for each individual (affected or un-
affected) to capture rare heterozygous variants of
cardiomyopathy genes, excluding Titin (TTN)
missense variants (Supplemental Table 1). Further
ﬁltering and annotation were conducted as previ-
ously reported (17). Single nucleotide polymorphisms
that occurred in <1% in the general population (on
the basis of the 1,000 Genomes Project and NHLBI
[National Heart, Lung, and Blood Institute] GO ESP
[Exome Sequencing Project] [19,20]), and were pre-
dicted to be damaging in at least 1 of the prediction
algorithms, were selected to generate DCM “candidate
gene” lists. Finally, Endeavour, a system biology
ranking algorithm, was accessed publicly to prioritize
the putative disease-causative genes (21,22)
(Supplemental Table 2). The U.S. family DNA samples
underwent genetic analysis as directed by the manu-
facturer using the Illumina TruSight One Sequencing
Panel. All candidate gene variants underwent conﬁr-
mation by Sanger sequencing.
ZEBRAFISH. Male and female wildtype zebraﬁsh
(Danio rerio) were maintained according to standard
protocols (23). Fish were cared for in the zebraﬁsh
core aquarium at the University of Colorado Denver
Anschutz Medical Center in Aurora, Colorado, and at
Colorado State University in Fort Collins, Colorado.
Zebraﬁsh experiments were approved by the Institu-
tional Animal Care and Use Committee at the Uni-
versity of Colorado Denver (protocol B-748139(04)
01D) in accordance with the care and use of animals
for scientiﬁc purposes. The zebraﬁsh offspring
were bred according to standard protocol (23). Fish
were anesthetized using tricaine methanesulfonate
(3-amino benzoic acidethylester; Sigma, St. Louis,
Missouri) at a ﬁnal concentration of 0.16% in 1  E3
embryo medium (5 mmol/l NaCl, 0.17 mmol/l KCl,
0.33 mmol/l CaCl, 0.33 mmol/l MgSO4 in H20). Fish
were staged between 48 and 72 h post-fertilization
(hpf) as previously described (24).
ZEBRAFISH MICROINJECTION. The effects of ﬁlamin
Cb (ﬂncb) knockdownwere studied with a targeted MO
previously described by Ruparelia et al. (25). Control
ﬁshwere uninjected zebraﬁsh embryos, 25-Nþp53MO-
injected ﬁsh (25-N is a 25-base pair oligonucleotide
mixture generated from random sequences), and p53MO-injected zebraﬁsh (26). MO were obtained from
Gene Tools (Gene Tools, LLC, Philomath, Oregon) (27).
p53 MO (50-GCGCCATTGCTTTGCAAGAATTG-30) was
coinjected to reduce off-target effects (17). Then, 2 nl of
control and ﬂncbMO (250 mmol/l in 1 Danieu solution
with 0.5% rhodamine dextran [Invitrogen, Thermo
Fisher Scientiﬁc, Waltham, Massachusetts]) solution
were microinjected into the fertilized embryo yolk at
the 1 to 2 cell stage. Embryos that did not integrate
rhodamine dextran into the chorion by 4 hpf were
removed from further analysis. Zebraﬁsh embryos
were maintained in 1  E3 solution at 28.9C. MO
studies were completed over a series of separate
experiments and the data were combined.
Cardiac phenotypes were scored at 48 and 72 hpf,
and percentage of survival was scored at 7 days
post-fertilization (dpf). Positive cardiac phenotype
scoring criteria were impaired contraction or ventricle
collapse and enlarged atrium or abnormal blood ﬂow,
or reduced heart looping. Off-target effects included
abnormal neurodevelopment and any abnormalities
seen in body parts away from the heart, such as the
tail. MO-injected and control embryos were treated
with 0.003% (200 mmol/l) 1-phenyl 2-thiourea to
inhibit pigmentation and optimize visualization of
heart function (28).
cDNA AND RT-PCR. Human ribonucleic acid (RNA)
was extracted from lymphoblast cells collected from
affected patient III:1 and healthy patients III:2
and II:3 (family TSFDC031) and used to generate com-
plementary DNA using Ambion kit Cat #75742 (Life
Technologies, Grand Island, New York), according to
manufacturer’s instructions. Human FLNC expression
was determined by real-time polymerase chain reac-
tion (RT-PCR) spanning exon 43 with the following
primers: F50-CCGGCGTGCCAGCCGAGTTCAGCAT-30
and R50-GTGTGCTTGTCACTGTCCAGCTCA-30. PCR
conditions were 94C for 10 min, followed by 14 cycles
at 94C for 30 s, 64C for 1 min (annealing temperature
dropped 0.5C per cycle), then 72C for 1 min, followed
by 30 cycles at 94C for 20 s, 54C for 1 min, 72C for 1
min, followed by 72C for 7 min.
Zebraﬁsh RNA was extracted from control and ﬂncb
MO-injected ﬁsh at 48 hpf with Ambion kit Cat
#75742, according to manufacturer’s instructions.
Primers located in exons ﬂanking the MO target site
for ﬂncb were F50-AGTAACCCCAATGCTTGTCG-30 and
R50-TGGCTTCAACCACAAAATCA-30. b-actin levels
were used as a control value, as previously described
by Ruparelia et al. (25).
WESTERN BLOT. Heart tissue was obtained from the
Adult Cardiac Tissue Bank maintained at University
of Colorado Denver. To prepare protein lysates,
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348frozen heart samples were homogenized with 350 ml
ice cold radioimmunoprecipitation assay lysis buffer
(to generate 1 to 5 mg/ml) consisting of 150 mmol/l
sodium chloride, 1.0% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecylsulfate, 50 mmol/l tris
pH 7.5, and Protease Inhibitor Cocktail (Sigma-
Aldrich); agitated for 2 h at 4C; diluted in 500 ml
2 Laemmli buffer containing 4% sodium dode-
cylsulfate, 10% 2-Mercaptoethanol, 20% glycerol,
0.004% bromophenol blue, and 0.125 mol/l tris HCl
pH 6.8; centrifuged at 10,000 revolutions/min for
5 min; and the pellet was discarded. Protein content
was quantiﬁed using a Bio-Rad RC DC Protein Assay
Kit (Berkeley, California). Lysates (25 mg total pro-
tein per lane) were processed as previously
described (29), with the following changes: 4% to
15% Mini-PROTEAN TGX precast protein poly-
acrylamide gels (Bio-Rad) were transferred to
Immuno-Blot PVDF membrane (Bio-Rad) overnight at
4C and incubated with primary antibodies in tris-
buffered saline tween-20 with 3% milk overnight at
4C using polyclonal rabbit anti-FLNC C-terminus
(HPA006135, 1:500; Sigma-Aldrich), polyclonal rabbit
anti-FLNC N-terminus (ARP64454_P050, 1:1,000;
Aviva Systems Biology, San Diego, California), and
monoclonal mouse anti–glyceraldehyde-3-phosphate
dehydrogenase–peroxidaseantibody (G9295, 1:10,000;
Sigma-Aldrich). The membrane was probed with
horseradish peroxidase-coupled secondary anti-
immunoglobulin G goat antirabbit antibody (A0545,
1:10,000; Sigma-Aldrich) in tris-buffered saline
tween-20 with 1% milk and signal visualized using
WesternBright ECL HRP detection kit (Advansta,
Menlo Park, California).
ZEBRAFISH HEART FUNCTION ANALYSIS. The
effects of MO injection on cardiac morphology were
observed in transgenic Tg(myl7:GFP) embryos that
express green ﬂuorescent protein (GFP) under the
control of the cardiac-speciﬁc myl7 (formerly cmlc2)
promoter, which enables visualization of cardiac
morphology (30).
Zebraﬁsh embryos were imaged with a high-speed
camera (Photron Fastcam SA3) attached to a bright
ﬁeld stereomicroscope. Videos 1, 2, and 3 were
acquired at 1,500 frames/s with a resolution of 1,310
pixels/mm. As previously described (31), spatiotem-
poral plots were extracted from video sequences and
used to calculate blood velocity and the diameter of
the atrioventricular junction oriﬁce. Flow rate curves
over the cardiac cycle were obtained by multiplying
the instantaneous mean blood velocity by the
instantaneous mean-cross-sectional atrioventricular
junction oriﬁce (assumed to be circular). Strokevolume (SV) (representing the net volume of blood
pumped to the body per cardiac cycle) was found by
integrating the instantaneous ﬂow rate curve over an
entire cardiac cycle. Cardiac output represents the SV
times the heart rate. The retrograde (reverse) fraction
or ﬂow (RF) describes the portion of total blood that
moves in the reverse direction through the atrioven-
tricular junction over the course of 1 cardiac cycle and
was calculated as a ratio of the volume of retrograde-
moving blood divided by the volume of forward-
moving blood (31,32).
TRANSMISSION ELECTRON MICROSCOPY. Flncbþp53
MO-injected embryos and uninjected control embryos
were prepared for transmission electron microscopy
(TEM) as described elsewhere (33). Silver to pale-gold
sections (60 to 90 nm) were cut using a diamond
knife on a Reichert Ultracut E ultramicrotome (Leica
Microsystems AG, Wetzlar, Germany) and mounted
on formvar-coated slot grids. Sections were post-
stained with uranyl acetate and lead citrate and
observed under a JEOL JEM-1400 TEM (Peabody,
Massachusetts) operated at 100 kV.
STATISTICAL ANALYSIS. In experiments deter-
mining heart rate, SV, cardiac output, and RF,
normality was tested with the Shapiro-Wilk test. The
Levene mean test was used to assess equal variance if
data were normally distributed. If data were not
normally distributed, the Kruskal-Wallis test was
performed without data transformation. Analysis of
parametric data was performed with analysis of
variance. Multiple comparisons were performed us-
ing either of the following methods: Tukey test or
Mann-Whitney U test with Bonferroni correction. All
analyses were performed with SigmaPlot software
(version 12.0, Systat Software, San Jose, California).
At 72 hpf and 7 dpf, zebraﬁsh cardiac phenotypes and
survivors were analyzed using a chi-square test to
detect signiﬁcant differences.
RESULTS
WHOLE EXOME SEQUENCING. Members of family
TSFDC029 were clinically characterized (Table 1), and
3 affected individuals underwent WES (Figure 1A).
Upon bioinformatic ﬁltering of identiﬁed poly-
morphisms, and conﬁrmation by Sanger sequencing,
an 8-candidate variant list that cosegregated in the 3
affected individuals was generated (Supplemental
Table 2). Further cosegregation analysis using sam-
ples from unaffected subjects was used to exclude
variants that were present in 2 or more unaffected
family members. All variants were excluded except
FLNC c.7251þ1 G>A (NM_001458). This variant was
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349found to be absent from the 1,000 Genomes Project,
GO ESP database, and ExAC (Cambridge, Massachu-
setts) (34). The variant was present in all affected
relatives and was missing from 3 of the 4 unaffected
family members. The clinically unaffected variant
carrier, individual III:7, was enrolled at age 34 years
with a history of palpitations and an unremarkable
echocardiogram; she declined any further clinical
follow-up. Of the variants excluded because of lack of
cosegregation, only ANK2 was associated with a car-
diac phenotype (long QT syndrome). However, the
affected family members did not show any change of
QT interval.
Family TSFDC031 (Figure 1B) also underwent WES
and yielded >40 variants after bioinformatic ﬁltering.
The identical FLNC c.7251þ1 G>A splicing variant
was detected and no other obvious candidate DCM
genes were identiﬁed. Although family structures of
TSFDC029 and TSFDC031 did not allow formal
haplotype analysis, we were able to analyze nearby
genotypes that showed consistency with a shared
ancestral haplotype.
Family DNFDC057 (Figure 1C) underwent genetic
analysis by the Illumina TruSight One Sequencing
Panel. A FLNC splicing variant (c.5669-1delG;
NM_001458) was detected in the proband as well as
affected relative II:2. This variant was found to also
be unique (absent from ExAC, the 1,000 Genomes
Project, and GO ESP databases).
FLNC PHENOTYPE AMONG PATIENTS. The pheno-
types of all affected DCM subjects were cardiac-
isolated with no evidence of skeletal muscle
disease or creatine kinase elevation (Table 1). All
3 families were characterized by a strong arrhyth-
mogenic trait.
In family TSFDC029, individuals II:6 and III:6 died
of sudden unexpected cardiac deaths at the ages of
54 and 34 years, respectively. Individual III:6 was
found post-mortem to have cardiomegaly. The pro-
band (III:4) died of noncardiac causes at age 64 years,
but exhibited frequent (>40/h) and repetitive pre-
mature ventricular contractions in the absence of
heart failure (New York Heart Association functional
class II). A second-degree relative (II:2) and the pro-
band’s son (IV:1) had evidence of mild DCM. As
described, the proband’s sister (III:7) did not
meet DCM criteria at the time of evaluation, having
normal ventricular function and dimensions, but she
was symptomatic for palpitations. Among family
TSFDC031, the proband (II:2) had a history of
well-compensated DCM and died of sudden unex-
pected death at the age of 48 years. His son (III:1)
exhibited supraventricular arrhythmias (recurrent
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350atrial ﬁbrillation and atrial tachycardia) before
showing DCM with mild left ventricular dysfunction
(Figures 1D and 1E). Overall, the rare FLNC variant in
the 2 families was 83% penetrant, with sudden
death occurring before the age of 55 years in 3 of
8 known or suspected carriers (38%).
In the third family, DNFDC057, the proband (II:1)
presented at the age of 46 years with polymorphic
sustained ventricular tachycardia and paroxysmal
atrial ﬁbrillation and was found to have DCM with
severe left ventricular dysfunction. After an initial
improvement with medical therapy, she deteriorated
and was transplanted at the age of 60 years. Her
brother (II:2) presented at the age of 53 years with
severe left ventricular dysfunction and frequent
premature ventricular contractions. Cardiac function
improved with medical therapy, but then progres-
sively worsened, leading to him being listed for a
left ventricular assist device.
FLNC TRANSCRIPT CHARACTERIZATION AND
WESTERN BLOT. The FLNC variant in families
TSFDC029 and TSFDC031 results in a G>A nucleotideFIGURE 2 Affected Individuals Carry a Mutation at the Intronic Bor
(A) Sanger sequenced chromatogram of healthy individual II:3 from famil
the same family (III:1) showing the FLNC c.7251þ1 G>A variant. (B) Rea
lymphoblastoid human cells for exons 41 to 45 spanning probe showing p
affected patient (A-III:1) and normal product in healthy relatives (H-II:3
splicing; thick, solid line (lower) shows exon 43 being excluded. bp ¼ btransition and is predicted to remove the splice donor
site for intron 43 (Figures 2A and 2C). RT-PCR revealed
a single 409 base pair fragment spanning exons
41 to 45 in healthy individuals (from family
TSFDC031, II:3 and III:2) and an additional 293 base
pair fragment in an affected subject (III:1) (Figure 2B).
Sanger sequencing conﬁrmed that this shorter prod-
uct lacked exon 43, producing a frameshift, which is
predicted to result in a premature truncation of the
protein 21 amino acids downstream of the mutation
site (Supplemental Figure 1).
Cardiac tissue allowed for RNA and protein isola-
tion from DNFDC057 affected proband II:1, which
showed decreased FLNC RNA expression (data not
shown) and reduced FLNC protein (Figures 3A and 3B)
when compared with a control sample.
ZEBRAFISH ﬂncb GENE. To further characterize
FLNC and its functional role in causing the DCM
phenotype, we studied the zebraﬁsh FLNC ortholog
ﬂncb. The FLNC gene is duplicated in the zebraﬁsh
genome (ﬂnca and ﬂncb), and the ﬂncb gene was
chosen for analysis on the basis of its greaterder of Exon 43
y TSFDC031 with a normal FLNC gene and an affected individual from
l-time polymerase chain reaction of ribonucleic acid isolated from
resence of shortened product (missing 116 nucleotides, exon 43) in an
and H-III:2). (C) Diagram of normal (upper) and aberrant (lower)
ase pair; nt ¼ nucleotide.
FIGURE 3 FLNC Cardiac Protein Expression Is Decreased
(A) Western blot analysis shows decreased FLNC protein
expression in affected individual II:1 (A-II:1) from family
DNFDC057, and (B) analysis of densitometry of Western blots of
affected subject A-II:1 relative to control subjects were normal-
ized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
SEM (n ¼ 2).
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351sequence similarity to the human FLNC gene than
the zebraﬁsh ortholog ﬂnca (25). Successful knock-
down of ﬂncb using the splice site ﬂncb MO was
conﬁrmed by RT-PCR (Supplemental Figure 2). RT-
PCR in ﬂncb MO-injected embryos indicated a loss
of normally spliced ﬂncb messenger RNA, but
detected the presence of multiple different-sized
product bands consistent with abnormal splicing.
Abnormal splicing in MO-injected embryos was
conﬁrmed by sequencing the most prominent band
(Supplemental Figure 2, arrow).ZEBRAFISH CARDIAC PHENOTYPE. Zebraﬁsh embryos
injected with ﬂncb MO showed more frequent cardiac
phenotypes and reduced survival (Supplemental
Figure 3) when compared to control embryos. Fewer
than 25% of ﬂncb MO-injected zebraﬁsh embryos
without p53 MO exhibited 1 or more of the following
phenotypes: death in the central nervous system, less
distinct morphology of the brain ventricles, noto-
chord defects, and body length defects (data not
shown). These phenotypes are consistent with pre-
viously described off-target defects associated with
ectopic up-regulation of the p53 pathway caused by
MO injection in general (35). Note that ﬂncb is not
expressed in the brain or notochord. Indeed, the
incidence of these phenotypes was markedly reduced
in embryos coinjected with p53 MO.
Injection of ﬂncbþp53 MO led to a signiﬁcantly
greater number of embryos displaying a cardiac
phenotype when compared with control embryos
(uninjected, p53 MO, and scrambled 25-Nþp53 MO)
(percentage of embryos with a cardiac phenotype and
sample size at 72 hpf: uninjected ¼ 1.95%, n ¼ 411; p53
control-injected embryo ¼ 0.72%, n ¼ 139; 25-Nþp53
control-injected embryo ¼ 4.27%, n ¼ 351; ﬂncbþp53
MO-injected ¼ 72.61%, n ¼ 241; p ¼ 1.04  10-83 for
comparison of uninjected versus ﬂncbþp53 MO)
(Figure 4A). In addition, survival at 7 dpf among the
ﬂncb MO-injected embryos was signiﬁcantly lower
than for control embryos (percentage of survival at 7
dpf relative to sample size on day 0: uninjected ¼
97.08%, n ¼ 411; p53 control-injected embryo ¼
97.12%, n ¼ 139; 25-Nþp53 control-injected
embryo ¼ 96.58%, n ¼ 351; ﬂncbþp53 MO-injected
embryo ¼ 71.95%, n ¼ 164; p ¼ 1.65  10-19 for
comparison of uninjected versus ﬂncbþp53 MO)
(Figure 4A).
The transgenic GFP-injected ﬂncbþp53 MO zebra-
ﬁsh embryos at 48 and 72 hpf demonstrated pericardial
edema, dysmorphic or dilated cardiac chambers, and
abnormal looping of the heart tube suggestive of sys-
tolic dysfunction (Figures 4B and 4C). By 48 hpf, 9% of
ﬂncbþp53 MO lacked circulation entirely, indicating a
functional cardiac defect. The remaining 91% had
varying degrees of reduced blood circulation, accom-
panied by an increase in retrograde blood ﬂow
and overall weaker contractility. Heart function in
the latter group was assessed by video analysis
(Videos 1, 2, and 3), which indicated that the mean RF
was signiﬁcantly increased in ﬂncbþp53 MO embryos
(0.061) relative to uninjected control embryos (0.017)
and 25-Nþp53 MO control embryos (0.008) (Figure 5A).
RF and heart ratewere normally (Gaussian) distributed
according to the Shapiro-Wilk test: analysis of variance
indicated a significant difference among treatments
FIGURE 4 MO Knockdown of ﬂncb in Zebraﬁsh Showing a Cardiac Phenotype
(A) Black bars: percentage of surviving embryos with severe cardiac phenotype at 72 h post-fertilization (hpf) for uninjected (n ¼ 411), p53
morpholino (MO)-injected (n ¼ 139), 25-Nþp53 control MO-injected (n ¼ 351), and ﬁlamin Cb (ﬂncb)þp53 MO-injected (n ¼ 241); *p ¼ 1.04 
10-83 (for comparison of uninjected heart vs. ﬂncbþp53 MO using chi-square testing). Gray bars: percentage of surviving embryos at 7 days for
uninjected (n ¼ 411), p53 MO-injected (n ¼ 139), 25-Nþp53 control MO-injected (n ¼ 351), and ﬂncbþp53 MO-injected (n ¼ 164); †p ¼ 1.65 
10-19 (for comparison of uninjected embryo vs. ﬂncbþp53 MO using chi-square testing). (B) Representative zebraﬁsh heart pictures for embryo
uninjected and ﬂncb MO coinjected with p53 MO zebraﬁsh embryos at 48 hpf. The ﬂncbþp53 MO-injected zebraﬁsh show cardiac phenotype
(pericardial edema [P]), and GFP hearts showing less heart looping, elongated atrium, pericardial edema, and a truncated ventricle. (C)
Representative zebraﬁsh heart pictures for embryo uninjected and ﬂncb MO coinjected with p53 MO zebraﬁsh embryos at 72 hpf. Among the
ﬂncbþp53 MO-injected zebraﬁsh, they show cardiac phenotype, and GFP hearts further show less heart looping, elongated atrium, pericardial
edema, and a truncated ventricle.
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352(p ¼ 6.1  10-5), and post hoc Tukey test indicated
that ﬂncbþp53 MO embryos demonstrated signiﬁcant
differences in RF by 48 hpf relative to both unin-
jected embryos and 25-Nþp53 MO-injected embryos
(p ¼ 0.023 and p ¼ 0.007, respectively), whereas the 2
control embryos were not different from each other(p ¼ 0.420). In addition, heart rate was slower in
ﬂncbþp53MO embryos relative to both types of control
embryos (Figure 5B). SV (p ¼ 0.482) and cardiac output
(p¼ 0.293) were not normally distributed, and in these
cases, the Kruskal-Wallis test was used. Despite car-
diac malformation and defects related to patterns of
FIGURE 5 Morphological Analysis Demonstrating Impaired Cardiac Function of ﬂncbþp53 MO-Injected Zebraﬁsh Embryos
High-speed videos of hearts in 48 hpf embryos were analyzed using custom MATLAB software (Mathworks, Natick, Massachusetts) (23,24).
Embryos injected with ﬂncþp53 MO (n ¼ 21) were compared with uninjected control embryos (n ¼ 17) and control embryos injected with a
scrambled MO (25-Nþp53 MO; n ¼ 11). (A) Mean reverse ﬂow fraction (SE) for each treatment (uninjected: 0.017, 25-Nþp53 MO: 0.008,
ﬂncbþp53 MO: 0.061). Signiﬁcant differences were observed for ﬂncbþp53 MO-injected relative to control embryos by analysis of variance
(ANOVA) (p ¼ 6.1  10-5). Follow-up Tukey tests indicated differences between ﬂncbþp53 MO and uninjected embryos (p ¼ 0.023); and
ﬂncbþp53 MO compared with 25-Nþp53 MO (p ¼ 0.007), but no difference between the control embryos (p ¼ 0.420). (B) Mean heart rate
(SE) for each treatment (uninjected: 193.5 beats/min [bpm], 25-Nþp53 MO: 181.0 bpm, ﬂncbþp53 MO: 162.0 bpm (ANOVA; p ¼ 2.1  10-7).
ﬂncbþp53 MO decreased the heart rate at 48 hpf compared with both uninjected embryos and 25-Nþp53 MO-injected embryos. (***p ¼ 0.001,
***p ¼ 0.005, respectively, by Tukey Test); heart rates of uninjected versus 25-Nþp53 MO were not different (p ¼ 0.118). (C) Mean stroke
volume (SE) for each treatment (uninjected: 0.125 nl, 25-Nþp53 MO: 0.185 nl, ﬂncbþp53 MO: 0.100 nl). No signiﬁcant difference was
detected between treatments (Kruskal-Wallis 1-way ANOVA on ranks; p ¼ 0.482). (D) Mean cardiac output (SE) for each treatment (unin-
jected: 24.4 nl/min, 25-Nþp53 MO: 32.6 nl/min, ﬂncbþp53 MO: 16.0 nl/min). No signiﬁcant difference was detected between treatments
(Kruskal-Wallis 1-way ANOVA on ranks; p ¼ 0.293). For Videos 1, 2, and 3, please see the online version of this article. Abbreviations as in
Figure 4.
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353contraction, ﬂncbþp53 MO-depleted embryos were
able to maintain normal SV (Figure 5C) and normal
cardiac output (Figure 5D) through the ﬁrst 2 days of
development.
ZEBRAFISH ﬂncb IS ESSENTIAL FOR SARCOMERIC
ORGANIZATION AND Z-DISC STABILITY. The reducedcontractility observed in ﬂncbþp53 MO-injected em-
bryos suggests that the contractile apparatus was
abnormal in these hearts. We investigated the role of
ﬂncb in sarcomere structure in transverse sections of
the zebraﬁsh embryonic ventricle (Figure 6). By 72 hpf,
wild-type hearts had assembled arrays of nascent
myoﬁbrils composed of consecutive sarcomere units,
FIGURE 6 Ultrastructural Analysis Indicates Deﬁciencies in Sarcomere Organization and Z-Disc Formation
Transmission electron micrographs of zebraﬁsh hearts at 72 hpf indicate that (A) wild-type embryos had assembled several consecutive sar-
comeres with clearly distinct Z-discs (black arrow), whereas ﬂncbþp53MO hearts (B to F) show evidence of disorganized ultrastructure. (B)Most
Z-discs were diffusely stained, irregular in shape (black arrowheads), or seemingly absent (white arrowheads). Insets: Cross section through
myoﬁlament bundles indicated a normal primary organization of thick and thin ﬁlaments in hexagonal lattices in ﬂncb-depleted hearts. (C)
Sarcomere arrangement in myoﬁbrils (m) was often nonconsecutive, with (D) multiple sarcomeres sometimes adjoined to a mass of Z-disc-like
material (z). (E) Small vacuoles (v) were often present between or near the plasmamembranes of adjacent cardiomyocytes. These vacuoles could
be large, creating a gap between adjacent cells. (F) Autophagic vesicles (a) were observed. Scale bar: 1 mmol/l. Abbreviations as in Figure 4.
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354joined by distinct Z-discs (Figure 6A). In contrast,
ﬂncbþp53 MO embryos showed myoﬁbrils composed
of fewer consecutive sarcomeres, or myoﬁbrils in ab-
normal arrangements with Z-discs (Figures 6B to 6D).In most cases, Z-discs appeared irregular or were
seemingly absent. However, cross sections revealed
that the primary arrangement of thick and thin ﬁl-
aments into hexagonal lattices appears normal,
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355suggesting that initial sarcomerogenesis was
normal, but that myoﬁbril growth was impaired.
Flncb-depleted cardiomyocytes developed small
vacuoles associated with, or near, the cell mem-
brane. In some cases, the vacuoles were quite large
(Figure 6E), suggesting that intercellular attach-
ments had ruptured. Potential autophagic vesicles
were observed in regions with highly disorganized
sarcomeres (Figure 6F). Taken together, these data
point to an important role for ﬂncb in maintaining
sarcomere stability and cardiomyocyte attachment
as mechanical stress increases in the developing
embryonic heart.
DISCUSSION
This report presents 2 rare splicing variants in FLNC
cosegregating in 3 families with DCM; both
c.7251þ1G>A and the c.5669-1delG variants were ab-
sent from all queried databases (1,000 Genomes
Project, NHLBI GO ESP, and ExAC). Interestingly,
c.7251þ1G>A was detected in 2 Italian families that
reside in the same region of Italy. This ﬁnding sug-
gests a founder-effect that is not unprecedented in
FLNC, as a W2710X FLNC variant was reported in
31 individuals of 4 German families with myoﬁbrillar
myopathy (MFM; MIM#609524) (36). Furthermore,
FLNC variants have reduced penetrance, as described
in familial DCM (4). FLNC variant carriers in our study
showed an arrhythmogenic trait, with high incidence
of sudden cardiac death. Remarkably, arrhythmias
were also reported in restrictive cardiomyopathy
(atrial ﬁbrillation, conduction disease) and HCM
(sudden cardiac death) associated with FLNC variants
(13,14).
FLNC is primarily expressed in striated muscle,
where it clearly plays an important role on the
basis of its association with myoﬁbrillar myopathies
(10,12,36,37). The FLNC protein is relatively speciﬁc
to skeletal and cardiac muscle, where it is has been
shown to be an actin-cross-linking protein and in-
teracts with the dystrophin-associated-glycoprotein
complex, integrin, and Z-disc proteins (FATZ-1,
myotilin, myopodin), suggesting its role is to provide
mechanical stability within the sarcomere (37,38).
Variants in FLNC cause MFM (MIM#609524), a
disease characterized by disintegration of skeletal
muscle ﬁbers, ﬁrst reported in a German family with a
nonsense mutation in FLNC with autosomal domi-
nant inheritance and presentation of limb girdle
myopathy (12). Variants in FLNC leading to skeletal
myopathies include protein-coding missense muta-
tions, insertion/deletion mutations, frameshift de-
letions, and nonsense mutations. These mutationsare distributed across the protein, including the
NH3-terminal actin-binding domain (8), the central
immunoglobulin-like domains (9–11,39), and the
COOH-terminal dimerization domain (12).
As has been demonstrated with other ﬁlamins
(FLNA and FLNB), the phenotype displayed in
affected FLNC patients varies with the position of the
mutation and the functional domain affected (8,37).
The FLNC gene mutation c.5160delCfs (p.Phe1720-
LeufsX63) (9) has been shown to lead to nonsense-
mediated decay, resulting in reduced messenger
RNA levels with undetectable expression of the
mutant allele and reduced protein levels as shown
by staining in muscle biopsies (37). Our study
demonstrated an abnormal splice product and
reduced cardiac FLNC protein levels related to FLNC
splicing variants. Loss-of-function (LoF) variants are
uncommon in FLNC, as evidenced by data from
ExAC. In over 60,000 sequenced individuals, the
frequency of FLNC LoF variants is lower than ex-
pected, leading to a high probability of LoF intol-
erance for FLNC (40). Collectively, these data
support the notion that the variants reported here
affect splicing, reduce cardiac FLNC protein levels,
and are likely poorly tolerated from an evolutionary
perspective.
A subset of mutated FLNC myopathy patients have
reported “cardiac phenotypes,” with 1 study report-
ing one-third of patients having overt cardiac abnor-
malities, including conduction blocks, tachycardia,
diastolic dysfunction, and left ventricular hypertro-
phy (36). Recently, cases of familial HCM in the
absence of muscle involvement have been reported.
Valdes-Mas et al. (14) demonstrated that patients
with the cardiac-restricted phenotype of HCM had
FLNC mutations (8 different nonsense and missense
variants in 9 families) mapping to the actin-binding
and immunoglobulin-like domains, with a pene-
trance of >87%. As with our patients, none of the
patients with HCM exhibited MFM. More recently,
missense mutations (FLNC c.4871 C>T and c.6478
A>T) were found among restrictive cardiomyopathy
patients who also had no evidence of skeletal muscle
abnormalities (13). This provides evidence that FLNC
missense mutations can also lead to disease through
a variety of mechanisms. The published reports
show increased recognition of FLNC importance in
cardiomyopathy.
Our ﬁnding of a cardiac-restricted phenotype of
DCM in 2 Italian families carrying the identical
FLNC mutation in addition to a U.S. family with
a different FLNC mutation further ampliﬁes the
complexity of FLNC-associated pathology and raises
the question of the source of the observed clinical
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356variability. Certainly part of this variability resides
in the biochemical functions of different parts of
the FLNC protein, as well as in the nature of the
mutation (nonsense, missense, splicing). In the case
of our patients no skeletal muscle tissue was
available for analysis. However, the cardiac tissue
we examined showed decreased levels of FLNC
protein expression for the N- and C-terminal ends.
This apparent reduction in FLNC protein from
an explanted human heart harboring the c.5669-
1delG splicing variant supports a haploinsufﬁciency
model.
Previous studies may not have appreciated FLNC
mutations in cardiomyopathy populations in the
absence of other muscle involvement due to its
absence from current clinical DCM and HCM genetic
screening panels. We expect that as WES is expanded
in the clinic, more “atypical” presentations of muta-
tions in FLNC (and other genes) will be identiﬁed.
Among our 3 families, in which 2 families shared 1
mutation, the FLNC variant did not cause skeletal
muscle phenotype, but was associated with a
high risk of arrhythmia and a risk of sudden death.
The supraventricular and ventricular arrhythmias
occurred in spite of nonsevere left ventricular
dysfunction and dilation. Our zebraﬁsh data support
this model, and functional reduction in expressed
ﬂncb caused looping and chamber morphogenesis
abnormalities in the heart tube, reduced systolic
function, altered patterns of embryonic blood ﬂow,
and the development of a cardiac edema phenotype.
Our data show that knockdown of ﬂncb causes a se-
vere and irreversible cardiac phenotype that leads to
increased death once embryos become dependent on
their circulatory system for survival. Although it has
not been absolutely proven that embryos died at 7 dpf
because of cardiac insufﬁciency, there is a strong
presumption given the demonstrated cardiac pheno-
type and the fact that a large majority of zebraﬁsh
with mutations in essential cardiac genes all die about
7 dpf. Before day 7, mutant embryos remain alive
even when the heart is completely noncontractile,
because they obtain oxygen via diffusion through
their skin (41,42).
These ﬁndings suggest that knockdown of ﬂncb
in zebraﬁsh induces poor systolic function that is
required for normal cardiac morphology and con-
tractile behavior. There is a difference in the severity
of the phenotypes, which is not unexpected because
the human subjects are heterozygous and experi-
encing late-onset phenotype, whereas our zebraﬁsh
model depicts the consequences for embryonic, full,
or strong LoF of FLNC.To better evaluate contractile function in zebraﬁsh
embryos, we examined the ultrastructure of car-
diomyocytes at 72 hpf by TEM. In contrast to the
well-arranged sarcomere structures of the wild-type
control hearts, ﬂncbþp53 MO hearts showed sarco-
mere organization defects. In particular, most Z-discs
were irregular or seemingly missing in ﬂncbþp53
MO embryos. The Z-disc is a complex multiprotein
structure that links the sarcomere, costamere, and
sarcolemma within heart and skeletal muscle. Z-discs
provide mechanical integrity to the sarcomere that
allows it to withstand large forces associated with
contraction. Moreover, the Z-disc can serve as an
integrative site involved both in receiving and
transmitting signals associated with biomechanical
and biochemical pathways (43–45). Z-discs are
required for myoﬁbril stability (43,46) and the pres-
ence of compromised Z-discs is often accompanied
by disrupted sarcomeres (43). The cardiac ultra-
structural defects in ﬂncbþp53 MO hearts likely un-
derlie the weaker contractility of these hearts, which
would in turn impact the pattern of blood ﬂow.
The structural abnormalities in Z-discs of ﬂncbþp53
MO hearts is particularly intriguing because muta-
tions in several Z-disc components are known to
cause DCM (47–50).
The ultrastructural phenotypes observed in zebra-
ﬁsh ﬂncbþp53 MO cardiomyocytes share certain
commonalities with skeletal muscle phenotypes
observed in knock-in mice heterozygous for a patient
mimicking a FLNC mutation (51), including the
dissolution of Z-discs and presence of possible
autophagic vesicles. However, differences are also
apparent. Z-disc streaming, the degeneration of
intermittent myoﬁbrils, and mitochondrial enlarge-
ment were not observed in zebraﬁsh hearts at 72 hpf.
However, further study is required to determine
whether ﬂncb-depletion phenotypes in cardiac versus
skeletal muscle are fundamentally different. Alter-
natively, zebraﬁsh hearts at later stages of develop-
ment, or under stressed conditions, might show
phenotypes more akin to those of the skeletal muscle
of FLNC heterozygous mice. Many human MFM pa-
thologies, including ﬁlaminopathies, exhibit cyto-
plasmic protein aggregates in skeletal muscle, and
recent evidence indicates their presence as well in
adult cardiac tissue of patients heterozygous for
FLNC mutations (13,14). Whereas our studies did not
identify such aggregates in the 72 hpf zebraﬁsh
embryonic heart, a broader study should investigate
aggregate-speciﬁc markers and additional ages or
conditions to clarify whether and when protein
aggregates appear in this model.
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357A recent report of Chevessier et al. (51), described
Z-line lesions in a FLNC p.W2710X heterozygous
mouse model, preceding the classical MFM protein
aggregates that characterize the FLNC disease. Inter-
estingly, these lesions were greatly increased in
number following acute physical exercise in mice.
The investigators suggested that the mutant ﬁlamin
inﬂuences the mechanical stability of myoﬁbrillar
Z-discs. In this regard, in our patients there was no
history of intense exercise in any of the affected in-
dividuals in the 3 pedigrees to potentially explain
differences in age of onset or severity of phenotypes,
and there was no association of exercise with major
ventricular arrhythmic events and sudden cardiac
death.
STUDY LIMITATIONS. A limitation of the zebraﬁsh
model is that detailed phenotypic analysis in MO
knockdown studies is most reliable for only the ﬁrst
few days of development. Although we have not
examined the functional activity of proteins result-
ing from mis-spliced transcripts of zebraﬁsh ﬂncb
messenger RNA, these proteins are likely to be
poorly functional because they would lack major C-
terminal portions of the protein, including several
immunoglobulin repeat regions, both hinge regions,
and the actin-binding regions (52). The current MO
studies indicate an essential requirement for FLNC
in the developing heart and demonstrate that its
loss causes cardiac dysgenesis via effects on cardiac
morphology, ultrastructure, and biomechanical dy-
namics (contractility and blood ﬂow). Whereas a
splice blocking MO that mimics the human allele
could be generated, a careful analysis would need
to be done to conﬁrm whether the resulting zebra-
ﬁsh phenotypes represent strong or only partial
LoF. Whereas this more subtle characterization of
allelic behavior could be very interesting, a Cas9
RNA-guided CRISPR (Clustered Regularly Inter-
spaced Short Palindromic Repeat) genome editing
approach would be strongly preferred to avoid the
limitations of MO, such as dose dependency and
off-target effects.
In this study, the ﬂncb gene was selected as the
initial candidate to test the hypothesis that FLNC
protein is critical for cardiac development, on the
basis of the 82% amino acid identity between zebra-
ﬁsh Flncb and human FLNC. The zebraﬁsh genome
also contains a ﬂnca ortholog that is reported to have
minimal cardiac expression (25). We have preliminary
data indicating that ﬂnca is indeed expressed in
48 hpf zebraﬁsh hearts, and further studies will
therefore be needed to generate ﬂnca mutants and
determine whether doubly mutant embryos havea stronger cardiac defect than do ﬂncb-depleted
embryos.
Cardiac tissue was unavailable from 2 of our fam-
ilies (TSFDC029 and TSFDC031), limiting our ability
to infer mechanisms beyond the data from the
affected heart studied from family DNFDC057. We
predict that our reported FLNC variants alter RNA
splicing, likely leading to reduced protein expression
and DCM via a haploinsufﬁciency model. The
reduced FLNC protein we report from an affected
explanted heart is consistent with this model, but
additional data are needed before concluding that
haploinsufﬁciency is the principal mechanism of
DCM in these families.
CONCLUSIONS
Using WES in families with previously unknown
causes of DCM, we have described 2 novel splice site
mutations in the FLNC gene, which cosegregated with
a severe cardiac phenotype characterized by a high
rate of arrhythmia and sudden death. The DCM
phenotype was cardiac-restricted with no skeletal
myopathy. The variants detected lead to abnormal
splicing and may mediate pathogenicity via hap-
loinsufﬁciency, as supported by our functional
zebraﬁsh data and Western blot analysis, suggesting
that approaches to augment endogenous FLNC pro-
tein could represent a treatment strategy in these
cases. Our data, together with 2 DCM population
screenings (53,54), the study of other cardiomyopa-
thies (HCM and restrictive) (13,14), and previous data
on MFM (4,10,12,36,37), suggest that FLNC rare vari-
ants can cause a spectrum of cardiac and skeletal
muscle phenotypes. Finally, studies in vivo (mice,
zebraﬁsh, and medaka ﬁsh) (25,51,55) further support
our ﬁndings that suggest FLNC mutations can lead to
sarcomeric structural changes and ultimately cause
cardiac dysfunction.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
search for genetic defects of approximately 50% of DCM
cases without a known cause continues. In this study, we
report that FLNC gene truncations cause DCM in 3 families
and provide in vitro and in vivo supportive evidence for
haploinsufﬁciency as the pathogenic mechanism. Our
data show that FLNC variants are capable of causing a
DCM phenotype without any overt skeletal muscle
involvement. These data are to be interpreted in the
context of previously reported FLNC myopathies
that appear to be restricted largely to skeletal muscle.
Concluding that FLNC variants are further capable of
leading to DCM adds to the growing interest and under-
standing of FLNC mutations in human muscle diseases
and sets the stage for further studies to determine
whether up-regulation or other manipulations of the
FLNC protein could be viable treatment strategies.
TRANSLATIONAL OUTLOOK: Although the identiﬁ-
cation of rare variants in FLNC represents an important
initial step, this ﬁnding needs to be supported by further
studies addressing the mechanisms by which FLNC
mutations may lead to cardiomyocyte dysfunction and
human cardiac disease.
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